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Tissue factor pathway inhibitor (TFPI) is a natural inhibitor that regulates the initiation of
coagulationby inhibiting tissue factor - activatedfactor VII (TF - FVIIa) in the presence of
activated factor X (FXa) (l). Although the precise role of TFPI in haemostasis is yet to be
determined,it’sabilityto inhibitTF - FVIIa in thepresenceof FXa suggeststhat is doeshave an
importantphysiologicalsignificance.
TFPI levelshavebeenreportedto be normalin a varietyof clinicalconditions,includingpatients
with lupus anticoagulants(2,3). Lupus anticoagulants(LA) are acquired inhibitors,generally
considered to be immunoglobulins, that interfere with in vitro phospholipid dependent
coagulation tests (4,5). There is current interest in LA due to the associated thrombotic
complicationsas seen in increasedrisk for venousand arterialthrombosisas well as pregnancy
complications(6). We have previouslyreporteddecreasedfunctionallevelsof TFPI in plasma
containingLA usinga fluidphaseassay,but normallevelswith a bindingassay (7). These low
levelsof TFPI were shownto be correctedwith the additionof excessTF (7).
As a continuationof this study, we again assessedTFPI levels in LA plasma using the same
fluid assay. The effect of using three different sourcesof tissue factor (recombinant,human
brainand rabbit brain thromboplastins)in the TFPI assaywas examined. Of most significance
was the apparentcorrectionof TFPIvaluesas thromboplastinlevelsincreased.
MATERIALSANDMETHODS
ReagentsandMaterials
Purified FVII and FX were purchased from Sigma ChemicalCompany, St. Louis, USA. A
recombinant TF, Innovin@was obtained from Baxter Diagnostics,Deeri3eld,Illinois, USA.
Rabbit brain thromboplastin,Gradiplastin@was kindly donated by Gradipore Ltd, Sydney,
Australia.Humanbrainthromboplastinwasextractedandpreparedessentiallyby the methodof
Hjort (8). The synthetic peptide substrate, S-2222, was purchased from Chromogenic,
Molndal,Sweden.
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Collectionof Samples
Citratedplasma (normaland LA positive)was obtainedby drawing9 parts wholeblood into 1
part 0.109 M sodium citrate, and cenrnfuging at 1200 g at 4°C for 10 minutes. Plasma was
collected and then centrifuged again at 3000 g at 4°C for 20 minutes. Venous blood was
collectedfrom 20 healthy donors,pooled for use as the referenceplasma and stored at -70”C.
This plasma was designated as containing 1 U/mL TFPI in the test system used. Plasma
(normaland LA positive)was heated at 56°Cfor 15 minutes, immediatelyprior to testing, to
remove clotting factor activity and fibrinogen. Plasma designated LA positive by accepted
criteria (9) (i.e. prolongationof the activatedpartial thromboplastintime, and increasedratios
with Dilute Russell’sViper Venom screening and confirmatory tests), were obtained from
clinicallaboratoriesand storedat -20”Cuntiltesting.
FluidPhaseAssay
FunctionalTFPI was measured as previouslydescribed (7). Briefly, a reaction mixture was
preparedusingequalvolumesof TF (neat),FVII (0.033U/mL),FX (0.025U/mL) and calcium
chloride (0.025 M), incubatedat room temperaturefor 30 minutes, then stored at -70°Cuntil
required.To thewellsof microtitretrays50 pL of plasmaand 50 l.LLaliquotsof reactionmixture
were added. .Afterincubationfor 10minutesat 37”C,50 pL of FX (0.4U/rnL)and S-2222(2.7
mM) were added and incubatedfor 25 minutesat 37”C. To terminate the reaction, 50 pL of
50%aceticacid was addedand the absorbanceread at 405nmon Titertek@Multiskanmicrotitre
tray reader. A five point standard curve was constructed for each concentration of
thromboplastinover a range of 0.25-2.00 U/rnL TFPI using dilutionsof normal plasma in
imidazolebuffer(containing0.05Mimidazole,O.IM NaCland 0.0186MHC1).
The TFPI assay was optimised for reagent activity with the three (neat) thromboplastins
(recombinant, rabbit brain and human brain) using normal plasma. Neat thromboplastin
reagents, as prepared by manufacturer’sinstructionsor publishedmethod, each resulted in a
prothrombintimeof 13-14 secondsusingnormalplasmaand alsoprovideda minimumchange
of 0.3 absorbanceunitsover a rangeof 0.25-2.00 U/rnLin the assaysystem.
Each thromboplastinwas testedat variousconcentrations(x 1/4,x 1/2,x 5, x 10 and x 20) of
the neat preparation. Standardcurve resultswere designatedacceptableif they met the above
criteria. Different concentrations of thromboplastins were prepared by dilution in the
recommendeddiluentor by alternatereconstitutionof lyophilisedmaterial.
StatisticalAnalyses
Student’st - testwas used to comparethe statisticaldifferencebetweenthemeansof the setsof
results. Valuesof P <0.05 wereconsideredto be statisticallysignificant.
RESULTS
Differentconcentrationsof all thromboplastinsweretestedfor the generationof standardcurves.
Acceptableresultswere obtainedusingrecombinantthromboplastinat Neat, x 5, x 10 and x 20
concentrations, human brain thromboplastin at all concentrations tested and rabbit brain
thromboplastinat x 1/2 and neat concentrations(Table I). The standardcurves for each neat
thromboplastinwere very similar in their characteristics. It shouldalso be noted that normal
plasmaas part of each standardcurveand a batchof 10normalplasmasproducednormalTFPI
resultsat each testedthromboplastinconcentration(resultsnot shown).
TFPI values in 29 LA positive sampleswere 0.57 U/mL +/- 0.40 U/mL (range: 0.14-1.32
U/n-L)using neat, 0.66 U/rnL +/- 0.30 U/mL (range:0.21-1.42 U/d) using x 5,0.79 WmL
+/- 0.36 U/t& (range: 0.32- 1.90 U/mL) using x 10 and 0.85 WJIIJ- +/- 0.22 UM- (WY:
0.53-1.29 U/mL) using x 20 concentrationsof the recombinantthromboplastin. There were
statisticallysignificantdifferencesbetweenmeanTFPI for neatand x 10,neatand x 20, x 5 and
x 10,x 5 and x 20 concentrationsof recombinantthromboplastin(P <0.05, student’st - test).
Therewere however,no statisticallysignificantdifferencesbetweenthe meansof the two setsof
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results using x 10 and x 20 (P = 0.1434, student’s t - test) nor between neat and x 5
concentrationsof the recombinantthromboplastin(P = 0.1133,student’st - test).
TFPI values in 29 LA positive samples were 0.39 U/mL +/- 0.20 U/mL (range: 0.20-1.12
U/mL) using x 1/4, 0.69 U/mL +/- 0.22 U/mL (range: 0.35-1.17 U/mL) using x 1/2, 0.98
U/mL +/- 0.31 U/mL (range:0.52-1.70 U/mL) using neat, 1.11U/mL +/- 0.44 U/mL (range
0.43-1.72 U/mL) using x 5, 1.10U/mL +/- 0.44 U/mL (range0.50-2.00 U/mL) using x 10
and 1.13U/mL +/- 0.38 U/mL (range:0.46- 1.70U/mL) using x 20 concentrationsof human
brain thromboplastin. There were statisticallysignificantdifferencesbetween x 1/4,x 1/2 and
neat concentrations (P < 0.05, student’s t - test), but not between x 5, x 10 and x 20
concentrationsof humanbrain thromboplastin(P> 0.05, student’st - test).
TFPI values in 29 LA positive samples were 0.67 U/mL +/- 0.18 U/mL (range: 0.26-1.00
U/mL) using x 1/2 and 1.07U/mL +/- 0.38 U/mL (range:0.51-1.82 U/mL) using neat rabbit
brain thromboplastin.There was a statisticallysignificantdifferencebetweenthe meansof the
two sets of data (P = 0.0001,student’st - test).
Thereis a statisticallysignificantdifferencebetweentheneatmean TFPI usingrecombinantand
neat human thromboplastins(P = 0.0001,student’st - test) and also between neat recombinant
and neat rabbit thromboplastins (P = 0.0001, student’st - test). There was no statistically
significantdifferencebetweenthe meanTFPI usingneathumanand neatrabbit thromboplastins
(P= 0.1565, student’st - test).
DISCUSS1ON
Previously,we have shownthat TFPI levels in LA positiveplasma were significantlyreduced
(7) when assessed in the fluid phase assay modified from Sandset et al, 1991 (10). The
modifiedsystemused a recombinantthromboplastinas the sourceof TF in the reactionmixture.
In this study, we examined TFPI levels in 29 LA positive samples using three different
thromboplastins;recombinant,rabbitbrainand humanbrain.
Essentially similar results were obtained using recombinant thromboplastin as described
previously (7) (0.57 U/mL +/- 0.40 U/mL vs 0.36 U/mL +/- 0.19 U/mL). The significantly
reduced functionalTFPI levels were thereforeagain demonstrated. The apparent discrepant
resultswhen usingrecombinantthromboplastinrequirefurtherinvestigation.We werealso able
TABLEI
TFPI Levelsof 29 LA PositivePlasmasAssessedUsing
ThreeDifferentThromboplastinsin a FunctionalTFPI Assay.
Thromboplastin Recombinant Human Rabbit
Cone. Mean SD Range Mean SD Range Mean SD Range
x 1/4 *** 0.39 0.20 0.20-1.12 ***
x 1/2 *** 0.69 0.22 0.35-1.17 0.67 0.18 0.26-1.00
Neat 0.57 0.40 0.14-1.32 0.98 0.34 0.52-1.70 1.07 0.38 0.51-1.82
x5 0.66 0.30 0.21-1.42 1.11 0.44 0.43-1.98 ***
x 10 0.79 0.36 0.32-1.90 1.13 0.38 0.46-1.70 ***
x 20 0.85 0.22 0.53-1.29 1.10 0.44 0.50-2.00 ***
Mean,StandardDeviation(SD)and Rangeof TFPI valuesareexpressedin U/mL.
*** Resultsnot attainablein TFPI assaysystemusingtheseconcentrationsof TF.
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to demonstratethe apparent“correction”of thesevalueswith theadditionof 20 foldrecombinant
thromboplastininto the assay system,as reportedpreviously(7). As an extensionof this study,
recombinantthromboplastinconcentrationat 5 fold and 10fold quantitiesin the assay system
were tested. MeanfunctionalTFPI wasclearlydemonstratedto increaseas the amountof TF in
the systemis increased. The increasein TFPI is statisticallysignificantwith theadditionof x 10
(F’ = 0.0076, student’s t - test) and x 20 (P = 0.001, student’s t - test) recombinant
thromboplastin.
Two other thromboplastinswere also testedin the assay system. Human brain thromboplastin
demonstratednormal functionalTFPI levels in the assay system(0.98 U/rnL +/- 0.31 U/mL).
These are very similarresults to thosereported by Jacobsener al, 1996(3). Their report does
not detail the sourceof TF, howeverwe assume humanbrain thromboplastinwas used. This
studyconfimlednormalTFPI levelswithneathumanbrainthromboplastin.Furthertestingwas
performedwith reducedand elevatedlevelsof humanbrain thromboplastin.When 1/4and 1/2
fold human brain thromboplastinwas used, significantlyreducedTFPI results were obtained.
Conversely, increased TFPI levels were reported when 5, 10 and 20 fold human brain
thromboplastinconcentrationswere used in the assay system. The differencesin these results
were not statistically significant. TFPI levels were normal using neat rabbit brain
thromboplastin,howeverthiswas significantlyreducedusing 1/2foldrabbit thromboplastin.
The findingsfrom this study supportthe hypothesisthatTFPI levelsdeterminedwith the fluid
phase assay in LA plasmais dependenton the type and concentrationof thromboplastinused.
Low TFPI results are againreportedusingthe recombinantthromboplastinunlessused at very
high concentration. The demonstrationof normal TFPI in LA positiveplasmas obtained by
Jacobsenet al, 1996(3) may be explainedwith the resultsobtainedin this study usinghuman
brainthromboplastinat differentconcentrations.
TF consistsof a specificapoproteincomplexedwith phospholipids(11). It is probablethatLA
target the phospholipidsof the complexresultingin the interferencedemonstratedin the TFPI
assay. This is supportedby the results demonstratedin this study, where TFPI levels in LA
plasmasappcmto be dependenton decreasingor increasingthromboplastinin the assay system.
Crude TF preparations, (e.g. human brain thromboplastin) may provide extraneous
membrane/phospholipidas partof theextractmilieuas wellas theTF complexfor LA to target.
LA may preferentiallytargetphospholipidsnotassociatedwith theTF complexresultingin the
apparent correction of TFPI values. Studies have commenced to elucidate the effect of
additionalpurifiedphospholipidsin theTFPI assay.
It is clear that the results from this study show that different thromboplastinshave varying
reactivitiesin theTFPI assayin thepresenceof LA, therecombinantthromboplastinin particular
showing the greatest sensitivity. This may be due the defined tissue factor apoprotein and
phospholipidcompositionof thisreagent. A similareffect has been shownwith the use of this
recombinantthromboplastinin thediluteprothrombintimeassayfor LA detection(12).
Theresultspresentedin thisreportclearlyindicatetheneedfor adequatelevelsof TF in theTFPI
fluid assay when a LA is presentin the test plasma. ExcessTF in the reaction mixture,or the
use of another technique not affected by LA, for example, the binding assay that has been
developed by Berrettini et al, 1995 (13) and that modified by this laboratory (7), appeal as
alternativetechniquesand are underfurtherinvestigation.
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